Logo

AstraZeneca Terminates Their License Agreement with Allergan for Brazikumab Signed in 2016

Share this

AstraZeneca Terminates Their License Agreement with Allergan for Brazikumab Signed in 2016

Shots:

  • AstraZeneca has completed its agreement with Allergan to recover the global rights to brazikumab (formerly MEDI2070). Both the companies have terminated their 2016 agreement and all rights to brazikumab- now returned to AstraZeneca
  • Allergan to fund up to an agreed amount- estimated to be the total costs expected to be incurred by AstraZeneca until completion of the development of brazikumab for CD and UC- including the development of a CDx
  • Pursuant to 2012 collaboration with Amgen- AstraZeneca will grant royalties on sales of brazikumab- if approved and launched. Brazikumab is mAb targeting IL23 and is in development for CD and UC with a companion biomarker

Click here to­ read full press release/ article 

Ref: AstraZeneca | Image: AstraZeneca 

 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions